Design Therapeuticsの空売り状況は、投資家がDesign Therapeuticsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Design Therapeutics (NASDAQ:DSGN) 株価情報, 空売り情報

Design Therapeutics

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Design Therapeutics Inc

Verisk Analytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>) has outperformed the market over the past 15 years by 4.07% on an annualized basis producing an average annual return of 15.69%. Currently, Verisk Analytics has a market capitalization of $38.91 billion. 
Buying $100 In VRSK: If an investor had bought $100 of VRSK stock 15 years ago, it would be worth $894.74 today based on a price of $275.58 for VRSK at the time of writing.
<h3>Verisk Analytics's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734649208_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

VRSK

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today

Jones Lang LaSalle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JLL#NYSE">JLL</a>) has outperformed the market over the past 20 years by 1.69% on an annualized basis producing an average annual return of 9.89%. Currently, Jones Lang LaSalle has a market capitalization of $11.72 billion. 
Buying $1000 In JLL: If an investor had bought $1000 of JLL stock 20 years ago, it would be worth $6,666.58 today based on a price of $246.93 for JLL at the time of writing.
<h3>Jones Lang LaSalle's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734648313_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Jones Lang LaSalle 20 Years Ago Would Be Worth This Much Today

BlackBerry Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) reported third-quarter financial results after the market close on Thursday. Here&#8217;s a look at the key metrics <a href="https://www.benzinga.com/pressreleases/24/12/ac42605872/blackberry-reports-third-quarter-fiscal-year-2025-results">from the quarter</a>.
Q3 Earnings: BlackBerry reported third-quarter revenue of $162 million. The company reported third-quarter adjusted earnings of two cents per share, beating analyst <a href="https://www.benzinga.com/calendars/earnings">estimates</a> for a loss of one cent per share, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
IoT revenue was&nbsp;$62&nbsp;million, up 13% year-over-year.&nbsp;Cybersecurity revenue totaled $93&nbsp;million in the quarter, up 7% year-over-year. Licensing revenue&nbsp;came in at $7&nbsp;million.
Total company gross margin was 74% in the quarter. Operating cash flow improved by $34 million year-over-year to $3 million. BlackBerry ended the quarter with $266 million in&nbsp;cash, cash equivalents and&nbsp;short-&nbsp;and long-term investments.
&#8220;BlackBerry achieved a significant inflection in its results this past quarter. Driven by a combination of strong revenue performance for both our Cybersecurity and IoT divisions, and continued focus on costs and efficiency, the company delivered stronger than expected profitability and a return to positive cash flow ahead of schedule,&#8221; said John Giamatteo, CEO of BlackBerry. 
From Last Week: <a href="https://www.benzinga.com/24/12/42477300/russian-state-backed-hackers-target-ukrainian-military-devices-via-spacexs-starlink-microsoft-report-reveals">Russian State-Backed Hackers Target Ukrainian Military Devices Via SpaceX&#8217;s Starlink, Microsoft Reveals</a>
Guidance: BlackBerry expects fourth-quarter revenue of $126 million to $135 million versus estimates of $161.49 million. The company anticipates fourth-quarter IoT revenue of $60 million to $65 million, secure communications revenue of $62 million to $66 million and licensing and other revenue of approximately $4 million.
BlackBerry expects full-year revenue of $517 million to $526 million versus estimates of $603.12 million. The company anticipates full-year adjusted earnings to be somewhere between breakeven and a loss of two cents per share, versus estimates for a loss of two cents per share.
Management will further discuss the quarter on a call with investors and analysts at 5:30 p.m. ET.
BB Price Action:&nbsp;<a href="https://www.benzinga.com/quote/BB" target="_blank" rel="noreferrer noopener">BlackBerry shares</a>&nbsp;were up 0.17% in after hours, trading at $2.98 at the time of publication Thursday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Courtesy of BlackBerry.

Earnings

Movers

Tech

BlackBerry Beats Q3 Earnings Estimates, But Soft Guidance Keeps Shares In Check

Legal

SVCO

Silvaco Says US Court Of Appeals For The Ninth Circuit Affirmed US District Court's Dismissal Of All Claims Brought By Aldini

ALLETE Says FERC Approved Proposed Transaction With CPP Investments And Global Infrastructure Partners

Guidance

PARR

Par Pacific Expects 2025 Capital Expenditure And Turnaround Outlay Guidance Of $210M - $240M

Marsh &amp; McLennan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) has outperformed the market over the past 10 years by 2.76% on an annualized basis producing an average annual return of 13.69%. Currently, Marsh &amp; McLennan has a market capitalization of $103.31 billion. 
Buying $100 In MMC: If an investor had bought $100 of MMC stock 10 years ago, it would be worth $360.25 today based on a price of $210.35 for MMC at the time of writing.
<h3>Marsh &amp; McLennan's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734647416_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Marsh & McLennan 10 Years Ago Would Be Worth Today

SPRY

ARS Pharmaceuticals Says Express Scripts Has Added neffy (Epinephrine Nasal Spray) To Its Commercial National Formularies

The Stock Repurchase Program will begin on December 19, 2024 and conclude on December 19, 2025.

Buybacks

FRST

Primis Financial Board Approves Stock Repurchase Program For Up To 740,600 Of Outstanding Shares Of Common Stock

As a result of this error, the Bank will record $8.1 million on a pre-tax basis of occupancy expense in the fourth quarter of 2024. On an after-tax basis, this will reduce fourth quarter diluted earnings per share by approximately $0.43.
As for the impact of ASC 842 in future years, it is expected that the correct calculation of lease expense will increase occupancy expense by approximately $1.6 million per year on a pre-tax basis.
It has evaluated the impact to income for each of the periods involved as well as the cumulative impact to 2024's results and have determined the understatement in the prior years as well as the impact to the results for 2024 are not material to the Bank's results of operations or its balance sheet.

PFBC

Preferred Bank Finds Unreconciled Difference In Its Calculation Of Its Right Of Use Asset And Lease Liabilities; Expects Additional Q4 Expense To Reduce Q4 EPS By $0.43

ASAI

Sendas Distribuidora Intends To Proceed With Voluntary Delisting Of Its ADSs From NYSE

BlackBerry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.01) by 300 percent. This is a 100 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $143.00 million which missed the analyst consensus estimate of $150.76 million by 5.15 percent. This is a 18.29 percent decrease over sales of $175.00 million the same period last year.

BlackBerry Q3 2025 Sales $143.00M Miss $150.76M Estimate

FCPT

Four Corners Property Trust Reports Acquisition Of A MercyOne Outpatient Clinic Property For $2.8M

BlackBerry is providing the following guidance for the fourth quarter and the full fiscal year 2025 (ending February 28, 2025).&nbsp;
As the sale of the Company's Cylance business is expected to close during the fourth quarter of 2024, that business is reported this quarter as discontinued operations, and the following guidance, except for non-GAAP basic EPS, is reflective solely of the expected results of the Company's continuing operations.

BlackBerry Now Expects FY25 Total Revenue Of $517M - $526M (Est $603.12M), Non-GAAP Basic EPS Of $(0.02) - Breakeven (Est $(0.02))

BlackBerry Expects Q4 Total Revenue Of $126M - $135M (Est $161.49M), Non-GAAP Basic EPS Of $(0.01) - $0.01 (Est $0.01)

Arch Capital Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NASDAQ">ACGL</a>) has outperformed the market over the past 10 years by 5.27% on an annualized basis producing an average annual return of 16.19%. Currently, Arch Capital Group has a market capitalization of $33.48 billion. 
Buying $100 In ACGL: If an investor had bought $100 of ACGL stock 10 years ago, it would be worth $446.81 today based on a price of $88.99 for ACGL at the time of writing.
<h3>Arch Capital Group's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734646508_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACGL

Here's How Much $100 Invested In Arch Capital Group 10 Years Ago Would Be Worth Today

Cohealyx is designed for tissue integration and revascularization to facilitate wound healing, reduce treatment timelines, and improve patient outcomes in the treatment of full-thickness wounds.

RCEL

AVITA Medical Secures FDA 510(k) Clearance For Cohealyx

Exchange-traded funds are rewriting the financial playbook, with 2024 marking a historic <a href="https://www.benzinga.com/etfs">year for the industry.</a>
From record-breaking flows to innovative fund launches, Bank of America detailed $1.6 trillion in ETF inflows this year in a new note. The global ETF market has grown to a staggering $15.1 trillion in assets under management. 
Additionally, ETF launches hit an all-time high of 1,485 in 2024, and institutional ownership continues to surge, cementing ETFs as the cornerstone of modern investment strategies. 
Here's how the ETF ecosystem is evolving — and why it matters.
<h3 class="wp-block-heading">Record Year for ETF Growth</h3>
The numbers speak for themselves: over the last five years, the global ETF market has grown at a robust 19% annualized rate, amassing more than $15 trillion in assets under management. 
In total, 15,866 ETFs have been created since 1993, with 2024 alone contributing 1,485 of those — a record for both active and U.S.-listed ETFs.
Institutional investors, retail traders and even cash-strapped mutual funds are gravitating toward ETFs for their liquidity, tax efficiency and cost advantages.
<h3 class="wp-block-heading">The Rise of Active ETFs: A Balancing Act</h3>
While ETFs have historically been dominated by passive strategies, active ETFs are making their presence known. Active funds accounted for 18% of total inflows in 2024, signaling a growing appetite for alpha strategies.
Still, passive funds remain the kingpin, representing over 50% of equity fund assets by AUM. 
In fact, 93% of ETFs track some type of index, but the allure of active management is pushing innovation. 
Investors seeking more active strategies in passive funds are also driving mutual fund-to-ETF conversions. According to Bank of America, this trend is likely to accelerate in the coming years as mutual funds struggle to remain relevant.
<h3 class="wp-block-heading">SPY vs. VOO: New ETF Champion in the Making?</h3>
The SPDR S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) remains the largest and most actively traded ETF since its inception in 1993. But its throne is being challenged.
Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) has a 6.5-basis-point lower expense ratio compared to SPY and could potentially surpass it in AUM by 2026.
In 2024, VOO registered more than six times the inflows obtained by SPY. 
<h3 class="wp-block-heading">Fund Flows: The Biggest Winners of 2024</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>ETF</th>
<th>Fund Flows YTD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vanguard S&amp;P 500 ETF (VOO)</td>
<td>$122.75 billion</td>
</tr>
<tr>
<td>iShares Core S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVV#NYSE">IVV</a>)</td>
<td>$48.97 billion</td>
</tr>
<tr>
<td>iShares Bitcoin Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NYSE">IBIT</a>)</td>
<td>$37.04 billion</td>
</tr>
<tr>
<td>Vanguard Total Stock Market ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTI#NYSE">VTI</a>)</td>
<td>$29.96 billion</td>
</tr>
<tr>
<td>Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)</td>
<td>$25.38 billion</td>
</tr>
<tr>
<td>iShares Core U.S. Aggregate Bond ETF (AGG)</td>
<td>$20.62 billion</td>
</tr>
<tr>
<td>SPDR Portfolio S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPLG#NYSE">SPLG</a>)</td>
<td>$19.91 billion</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Data: TradingView as of Dec. 19, 2024. </figcaption></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42594797/trump-wants-to-get-rid-of-the-debt-ceiling-30-year-treasury-bonds-fall-to-2024-lows-stocks-cut-gains">Trump Would &#8216;Lead The Charge&#8217; To Scrap Debt Ceiling: 30-Year Treasury Bonds Slide To 2024 Lows, Stocks Cut Gains</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

Broad U.S. Equity ETFs

Markets

ETFs

IBIT

SPLG

ETF Market Sets Records In 2024 As Inflows Reach $1.6 Trillion: 7 Funds Leading Charge

United States Steel Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) shares are trading lower in Thursday&#8217;s after-hours session after the company issued fourth-quarter guidance <a href="https://www.benzinga.com/pressreleases/24/12/b42604235/united-states-steel-corporation-provides-fourth-quarter-2024-guidance">below analyst estimates</a>.
What Happened: After the market close on Thursday, U.S. Steel said it expects to report a fourth-quarter adjusted loss of 25 cents to 29 cents per share. Fourth-quarter adjusted EBITDA is expected to come in around $150 million.
&#8220;Steel prices remained depressed and BR2 ramp-related costs exert pressure on the quarter, while the Big River team works towards increasing prime ton production in our new mill. Despite the challenging pricing environment across all segments, the North American Flat-Rolled segment continues to deliver strong EBITDA primarily through its robust commercial strategy and a diverse product mix,&#8221; said David Burritt, CEO of U.S. Steel.
Q4 Adjusted EBITDA By Segment:
<ul>
<li>The Flat-Rolled segment&#8217;s adjusted EBITDA is expected to be lower than the&nbsp;third quarter&nbsp;due to lower selling prices and volumes.</li>
<li>The Mini Mill segment&#8217;s adjusted EBITDA is expected to be lower than the&nbsp;third quarter&nbsp;due to lower volumes.</li>
<li>The European segment&#8217;s adjusted EBITDA is expected to be lower than the&nbsp;third quarter, largely due to the unfavorable impact of weak demand, resulting in lower volumes, average selling prices and volume inefficiencies.</li>
<li>The Tubular segment&#8217;s adjusted EBITDA is expected to be higher than the&nbsp;third quarter, primarily due to increased volume and lower costs due to the absence of outage activity.</li>
</ul>
&#8220;In Europe, the demand and pricing environment remains weak. To meet production volume requirements after unplanned downtime from a fire at the #1 Caster, we are temporarily operating three blast furnaces beginning Dec. 7, but expect to return to two blast furnaces by January. The Tubular segment continues to face pressure from a weak pricing environment,&#8221; Burritt added.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/12/42605034/fedex-stock-rallies-on-better-than-expected-q2-eps-freight-spin-off-announcement">FedEx Stock Rallies On Better-Than-Expected Q2 EPS, Freight Spin-Off Announcement</a>
U.S. Steel is due to report fourth-quarter financial results near the end of January. Analysts currently expect the company to report fourth-quarter revenue of $3.69 billion. Fourth-quarter earnings were projected around 16 cents per share before Thursday&#8217;s guidance update.
X Price Action: U.S. Steel shares were down 4.54% in Thursday&#8217;s after-hours session, trading at $30.28 at the time of publication, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Courtesy U.S. Steel

Commodities

After-Hours Center

US Steel Stock Stumbles On Weak Q4 Outlook

The ASR agreements will be completed under Kroger's recently announced $7.5 billion share repurchase authorization. Kroger is funding the share repurchases under the ASR agreements with existing cash on hand.

Kroger Enters Agreements For $5.0B Accelerated Share Repurchase Program

Larimar stock rallies 24% on FDA removal of partial clinical hold

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
<a href="https://investorplace.com/industries/healthcare/biotech/">Biotech stocks</a> are naturally an exciting area for investment. Just one therapeutic breakthrough can change the whole trajectory of the company. Millions of dollars, partnerships with big-name pharmaceuticals, or even a buyout can follow. However it entails a lot of risk. The Piper Sandler (NYSE:<a href="https://investorplace.com/stock-quotes/pipr-stock-quote/">PIPR</a>) investment firm says it found three biotech stocks with the winning ticket. These Piper Sandler stocks have investors curious. 



Piper Sandler may be the best bet for investors especially when you see where things are for biotech companies. The breakthrough drug discovery process can fail miserably. According to the American Society for Biochemistry and Molecular Biology, <a href="https://www.asbmb.org/asbmb-today/opinions/031222/90-of-drugs-fail-clinical-trials#:~:text=It%20takes%2010%20to%2015,candidates%20in%20clinical%20trials%20fail.">90% of all drug candidates</a> in clinical trials fail. Ouch!



Despite spending $1 billion on average, and waiting 10 to 15 years, most biotechs come up with nothing. That&rsquo;s why when they do succeed it is like hitting the lottery, because they have.



Piper Sandler believes they can post triple-digit returns over the next year. These Piper Sandler stocks are expected to grow by at least 100% in the next 12 months. Let&rsquo;s see why they feel confident these Piper Sandler stocks will double in price.



<h2>Piper Sandler Stocks to Buy: Context Therapeutics (CNTX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/orthopedic-therapy-1600-imac-300x169.png" alt="Physiotherapist doing healing treatment on patient leg. Therapist wearing blue uniform. Osteopathy, Chiropractic leg adjustment. Orthopedic therapy. ATIP stck."><div>Source: Microgen / Shutterstock</div></div>Context Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cntx-stock-quote/">CNTX</a>) is already off to the races. The biotech is up 80% so far in 2024 and has more than tripled over the past 12 months. Piper Sandler analyst Joseph Catanzaro initiated coverage of the stock last week with an overweight rating and set a market-high $4.50 per share one-year target price. Context stock currently trades around $2 per share, indicating 125% upside potential.



The analyst highlighted the potential of Context Therapeutics&rsquo; lead drug candidate, CTIM-76, which targets Claudin6 (CLDN6) in solid tumors. CLDN6 is one of the 27 family members of claudins that play an important role in tight adherence epithelial cell sheets that plays a significant role in cancer start and progression.



According to Investing.com CTIM-76 shows indications it <a href="https://www.investing.com/news/company-news/piper-sandler-bullish-on-context-therapeutics-stock-cites-ctim76-program-93CH-3443404">could be effective against</a> a broad range of CLDN6 expressions. That might let it be an effective therapy against different types of cancer, including ovarian and non-small cell lung cancer. Piper Sandler was bullish about the treatment&rsquo;s prospects heading into clinical testing.



Of course, Context Therapeutics is a pre-revenue stage company so its stock is going to be volatile but the market is backing this stock today.



<h2>Revance Therapeutics (RVNC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/health-medical-heart-1600-300x169.jpg" alt="hands holding a red heart shape against blue background symbolizing health"><div>Source: shutterstock.com/Anastasia Zagoruyko</div></div>Analyst David Amsellem reiterated his overweight rating of Revance Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rvnc-stock-quote/">RVNC</a>) though he lowered the one-year price target from $20 per share to $11 per share. That is still a 263% implied upside in the stock price.



Unlike Context Therapeutics, Revance does generate revenue from the sale of Daxxify, an alternative to the better known Botox made by AbbVie (NYSE:<a href="https://investorplace.com/stock-quotes/abbv-stock-quote/">ABBV</a>). The treatment lasts between six months and nine months whereas Botox averages three to four months.



First-quarter <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1479290/000147929024000099/rvnc-20240509.htm">revenue jumped 13%</a> to $51.9 million on higher Daxxify sales, which hit $22 million. Botox generates about $2 billion annually for AbbVie. Revance generated $29 million in sales of its RHA Collection, or Resilient Hyaluronic Acid, the only hyaluronic acid filler approved by the FDA for dynamic facial lines, wrinkles and folds. Daxxify is now also FDA-approved for the treatment of adults with cervical dystonia, a painful condition that causes the neck muscles to contract involuntarily, which causes the head to twist or turn to one side.



However, Revance stock has been on a long slide lower. Shares are down 65% in 2024 and over 90% for the past year. The stock collapsed after Revance posted bigger than expected losses last year and then continued falling after the biotech said it was <a href="https://www.investors.com/news/technology/rvnc-stock-collapses-as-prestige-plan-goes-up-in-smoke/">cutting prices on Daxxify</a> to better compete against Botox. It likely plays into why the Piper Sandler analyst nearly halved his price target.



<h2>Design Therapeutics (DSGN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/healthcare1600a-300x169.jpg" alt="stethoscope on a stock chart representing healthcare stocks to buy. Healthcare Stocks"><div>Source: Shutterstock</div></div>Design Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/dsgn-stock-quote/">DSGN</a>) went the other way when analyst Yasmeen Rahimi doubled her price target from $6 per share to $12 per share. She also upgraded her rating from neutral to overweight. Rahimi says the biotech has a diversified and innovative pipeline that provides a solid foundation for future growth.&nbsp;Trading at around $4.50 per share, the price target implies 167% growth ahead.



The analyst maintains the stock is value-priced yet offers solid financials and sufficient cash on hand to finance its drug development program. She believes the outlook for that program is positive, with promising outcomes for its DT-216P2, DT-168, and the upcoming drug candidates for Huntington&rsquo;s disease and myotonic dystrophy 1.



&#8203;&#8203;DT-216P2 is for the treatment of Friedreich Ataxia, a hereditary disorder that affects some of the body&rsquo;s nerves. DT-168 is for Fuchs endothelial corneal dystrophy, an eye disease that attacks the endothelial layer of the cornea.



Shares of Design Therapeutics are up 69% in 2024.



On the date of publication, Rich Duprey held a LONG position in ABBV stock. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.
<div>Rich Duprey has written about stocks and investing for the past 20 years. His articles have appeared on Nasdaq.com, The Motley Fool, and Yahoo! Finance, and he has been referenced by U.S. and international publications, including MarketWatch, Financial Times, Forbes, Fast Company, USA Today, Milwaukee Journal Sentinel, Cheddar News, The Boston Globe, L&rsquo;Express, and numerous other news outlets.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/05/the-100-club-piper-sandlers-3-top-picks-for-triple-digit-gains/">The 100%+ Club: Piper Sandler&#8217;s 3 Top Picks for Triple-Digit Gains</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

The 100%+ Club: Piper Sandler's 3 Top Picks for Triple-Digit Gains

Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

Lexeo stock drops 24% amid Friedreich Ataxia study results

Design Therapeutics GAAP EPS of -$0.21

RBC Capital analyst Leonid Timashev maintained a Hold rating on Design Therapeutics (DSGN – Research Report) yesterday and set a price target of $4...

RBC Capital Sticks to Their Hold Rating for Design Therapeutics (DSGN)

Leerink Partners analyst Joseph Schwartz has reiterated their neutral stance on DSGN stock, giving a Hold rating on August 5. Joseph Schwartz has g...

Design Therapeutics: A Cautious Hold Amidst Financial Stability and Clinical Progress

RBC Capital Remains a Hold on Design Therapeutics (DSGN)

Design Therapeutics GAAP EPS of -$0.23 beats by $0.02

Leerink Partners analyst Joseph Schwartz reiterated a Hold rating on Design Therapeutics (DSGN – Research Report) on November 7 and set a price tar...

Cautious Optimism for Design Therapeutics Amid Promising Developments and Financial Challenges

ABBV

ALPMF

ALPMY

BIIB

CNTX

DSGN

LRMR

LXEO

PIPR

PRME

PTCT

RVNC

SLDB

VYGR

Health Care

Press Releases

Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update

Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results

Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones

Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio

Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio

Comments

Design Therapeutics

空売り

Design Therapeutics (NASDAQ:DSGN) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル